Company Zevra Therapeutics, Inc.

ZVRA

US4884452065

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Zevra Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:35:12 2024-05-23 pm EDT			5-day change	1st Jan Change
4.52 ^USD	-2.38%		-5.04%	-30.99%

May. 13	Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call
May. 08	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

Number of employees: 67

USD in Million	2022	Weight	2023	Weight	Delta
Proprietary Prodrugs 100.0 %	10	100.0 %	27	100.0 %	+162.58%

USD in Million	2022	Weight	2023	Weight	Delta
United States and Europe 100.0 %	10	100.0 %	27	100.0 %	+162.58%

Managers	Title	Age	Since
Christal Mickle FOU	Founder	45	06-10-29
Neil McFarlane CEO	Chief Executive Officer	51	23-10-09
R. Clifton DFI	Director of Finance/CFO	51	15-03-31
Daniel Gallo CTO	Chief Tech/Sci/R&D Officer	-	23-01-30
Adrian Quartel CTO	Chief Tech/Sci/R&D Officer	63	Jan. 03
Sven Guenther CTO	Chief Tech/Sci/R&D Officer	52	06-12-31
Nichol Ochsner IRC	Investor Relations Contact	-	22-08-08
Abbi Maher LAW	General Counsel	-	23-01-30
Joshua Schafer PRN	Corporate Officer/Principal	53	23-01-08
Timothy Sangiovanni AUD	Comptroller/Controller/Auditor	40	17-02-12

Members of the board	Title	Age	Since
Wendy Dixon BRD	Director/Board Member	68	23-04-24
Tamara Favorito CHM	Chairman	65	21-08-17
Douglas Calder BRD	Director/Board Member	56	23-04-24
Christal Mickle FOU	Founder	45	06-10-29
Sven Guenther CTO	Chief Tech/Sci/R&D Officer	52	06-12-31
Corey Watton BRD	Director/Board Member	54	23-04-24
John Bode BRD	Director/Board Member	49	23-04-24
Thomas Anderson BRD	Director/Board Member	68	23-08-06
Alvin Shih BRD	Director/Board Member	47	Jan. 19
Neil McFarlane CEO	Chief Executive Officer	51	23-10-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	43,429,186	38,344,206 ( 88.29 %)	1,575,692 ( 3.628 %)	88.29 %

Name	Equities	%	Valuation
Nantahala Capital Management LLC 5.650 %	2,453,405	5.650 %	11 M $
BlackRock Advisors LLC 5.289 %	2,296,892	5.289 %	10 M $
Vanguard Fiduciary Trust Co. 3.924 %	1,704,006	3.924 %	8 M $
Woodline Partners LP 2.325 %	1,009,617	2.325 %	5 M $
683 Capital Management LLC 1.842 %	800,000	1.842 %	4 M $
Geode Capital Management LLC 1.812 %	787,020	1.812 %	4 M $
STATE STREET CORPORATION 1.573 %	683,172	1.573 %	3 M $
Janney Montgomery Scott LLC 1.520 %	660,169	1.520 %	3 M $
The Retirement Planning Co. of New England, Inc. 0.9906 %	430,193	0.9906 %	2 M $
Altium Capital Management LP 0.7863 %	341,461	0.7863 %	2 M $

Zevra Therapeutics, Inc.

1180 Celebration Boulevard Suite 103

34747, Celebration

+321 939 3416

http://zevra.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.63 USD

Average target price

19 USD

Spread / Average Target

+310.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ZEVRA THERAPEUTICS, INC.	-30.99%	194M
KYOWA KIRIN CO. LTD.	+9.28%	8.74B
SK BIOPHARMACEUTICALS CO., LTD.	-15.14%	4.94B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+50.73%	4.7B
YUHAN CORPORATION	+4.36%	3.98B
BETTA PHARMACEUTICALS CO., LTD.	-26.13%	2.28B
INDIVIOR PLC	+12.07%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.45%	2.14B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-33.59%	2.12B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals